Better guidelines for better care

accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling

Bruce Guthrie, Alexander Thompson, Siobhan Dumbreck, Angela Flynn, Phil Alderson, Moray Nairn, Shaun Treweek, Katherine Payne

Research output: Book/ReportOther Report

Abstract

Background:
Multimorbidity is common but most clinical guidelines focus on single diseases.

Aim:
To test the feasibility of new approaches to developing single-disease guidelines to better account for multimorbidity.

Design:
Literature-based and economic modelling project focused on areas where multimorbidity makes guideline application problematic.

Methods:
(1) Examination of accounting for multimorbidity in three exemplar National Institute for Health and Care Excellence guidelines (type 2 diabetes, depression, heart failure); (2) examination of the applicability of evidence in multimorbidity for the exemplar conditions; (3) exploration of methods for comparing absolute benefit of treatment; (4) incorporation of treatment pay-off time and competing risk of death in an exemplar economic model for long-term preventative treatments with slowly accruing benefit; and (5) development of a discrete event simulation model-based cost-effectiveness analysis for people with both depression and coronary heart disease.

Results:
(1) Comorbidity was rarely accounted for in the clinical research questions that framed the development of the exemplar guidelines, and was rarely accounted for in treatment recommendations. Drug–disease interactions were common only for comorbid chronic kidney disease, but potentially serious drug–drug interactions between recommended drugs were common and rarely accounted for in guidelines. (2) For all three conditions, the trials underpinning treatment recommendations largely excluded older, more comorbid and more coprescribed patients. The implications of low applicability varied by condition, with type 2 diabetes having large differences in comorbidity, whereas potentially serious drug–drug interactions were more important for depression. (3) Comparing absolute benefit of treatments for different conditions was shown to be technically feasible, but only if guideline developers are willing to make a number of significant assumptions. (4) The lifetime absolute benefit of statins for primary prevention is highly sensitive to the presence of both the direct treatment disutility of taking a daily tablet and competing risk of death. (5) It was feasible to use a discrete event simulation-based model to represent the relevant care pathways to estimate the relative cost-effectiveness of pharmacological treatments of major depressive disorder in primary care for patients who are also likely to go on and receive treatment for coronary heart disease but the analysis was reliant on eliciting some parameter values from experts, which increases the inherent uncertainty in the results. The key limitation was that real-life use in guideline development was not examined.

Conclusions:
Guideline developers could feasibly (1) use epidemiological data characterising the guideline population to inform consideration of applicability and interactions; (2) systematically compare the absolute benefit of long-term preventative treatments to inform decision-making in people with multimorbidity and high treatment burden; and (3) modify the output from economic models used in guideline development to examine time to benefit in terms of the pay-off time and varying competing risk of death from other conditions.

Future work:
Further research is needed to optimise presentation of comparative absolute benefit information to clinicians and patients, to evaluate the use of epidemiological and time-to-benefit data in guideline development, to better quantify direct treatment disutility and to better quantify benefit and harm in people with multimorbidity.
Original languageEnglish
PublisherNational Institute for Health Research
Volume5
DOIs
Publication statusPublished - Apr 2017

Publication series

NameHealth Services and Delivery Research
PublisherNational Institute for Health Research
No.16
Volume5
ISSN (Print)2050-4357
ISSN (Electronic)2050-4349

Fingerprint

Comorbidity
Economics
Guidelines
Health
Therapeutics
Economic Models
Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Coronary Disease
Depression
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Major Depressive Disorder
National Institutes of Health (U.S.)
Primary Prevention
Chronic Renal Insufficiency
Research
Tablets
Uncertainty
Primary Health Care
Decision Making

Cite this

Guthrie, B., Thompson, A., Dumbreck, S., Flynn, A., Alderson, P., Nairn, M., ... Payne, K. (2017). Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. (Health Services and Delivery Research; Vol. 5, No. 16). National Institute for Health Research. https://doi.org/10.3310/hsdr05160

Better guidelines for better care : accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. / Guthrie, Bruce; Thompson, Alexander ; Dumbreck, Siobhan; Flynn, Angela; Alderson, Phil; Nairn, Moray; Treweek, Shaun; Payne, Katherine.

National Institute for Health Research, 2017. (Health Services and Delivery Research; Vol. 5, No. 16).

Research output: Book/ReportOther Report

Guthrie, B, Thompson, A, Dumbreck, S, Flynn, A, Alderson, P, Nairn, M, Treweek, S & Payne, K 2017, Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. Health Services and Delivery Research, no. 16, vol. 5, vol. 5, National Institute for Health Research. https://doi.org/10.3310/hsdr05160
Guthrie B, Thompson A, Dumbreck S, Flynn A, Alderson P, Nairn M et al. Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. National Institute for Health Research, 2017. (Health Services and Delivery Research; 16). https://doi.org/10.3310/hsdr05160
Guthrie, Bruce ; Thompson, Alexander ; Dumbreck, Siobhan ; Flynn, Angela ; Alderson, Phil ; Nairn, Moray ; Treweek, Shaun ; Payne, Katherine. / Better guidelines for better care : accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. National Institute for Health Research, 2017. (Health Services and Delivery Research; 16).
@book{0ccb227a00da483aa2c49b601febc4d9,
title = "Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling",
abstract = "Background:Multimorbidity is common but most clinical guidelines focus on single diseases.Aim:To test the feasibility of new approaches to developing single-disease guidelines to better account for multimorbidity.Design:Literature-based and economic modelling project focused on areas where multimorbidity makes guideline application problematic.Methods:(1) Examination of accounting for multimorbidity in three exemplar National Institute for Health and Care Excellence guidelines (type 2 diabetes, depression, heart failure); (2) examination of the applicability of evidence in multimorbidity for the exemplar conditions; (3) exploration of methods for comparing absolute benefit of treatment; (4) incorporation of treatment pay-off time and competing risk of death in an exemplar economic model for long-term preventative treatments with slowly accruing benefit; and (5) development of a discrete event simulation model-based cost-effectiveness analysis for people with both depression and coronary heart disease.Results:(1) Comorbidity was rarely accounted for in the clinical research questions that framed the development of the exemplar guidelines, and was rarely accounted for in treatment recommendations. Drug–disease interactions were common only for comorbid chronic kidney disease, but potentially serious drug–drug interactions between recommended drugs were common and rarely accounted for in guidelines. (2) For all three conditions, the trials underpinning treatment recommendations largely excluded older, more comorbid and more coprescribed patients. The implications of low applicability varied by condition, with type 2 diabetes having large differences in comorbidity, whereas potentially serious drug–drug interactions were more important for depression. (3) Comparing absolute benefit of treatments for different conditions was shown to be technically feasible, but only if guideline developers are willing to make a number of significant assumptions. (4) The lifetime absolute benefit of statins for primary prevention is highly sensitive to the presence of both the direct treatment disutility of taking a daily tablet and competing risk of death. (5) It was feasible to use a discrete event simulation-based model to represent the relevant care pathways to estimate the relative cost-effectiveness of pharmacological treatments of major depressive disorder in primary care for patients who are also likely to go on and receive treatment for coronary heart disease but the analysis was reliant on eliciting some parameter values from experts, which increases the inherent uncertainty in the results. The key limitation was that real-life use in guideline development was not examined.Conclusions:Guideline developers could feasibly (1) use epidemiological data characterising the guideline population to inform consideration of applicability and interactions; (2) systematically compare the absolute benefit of long-term preventative treatments to inform decision-making in people with multimorbidity and high treatment burden; and (3) modify the output from economic models used in guideline development to examine time to benefit in terms of the pay-off time and varying competing risk of death from other conditions.Future work:Further research is needed to optimise presentation of comparative absolute benefit information to clinicians and patients, to evaluate the use of epidemiological and time-to-benefit data in guideline development, to better quantify direct treatment disutility and to better quantify benefit and harm in people with multimorbidity.",
author = "Bruce Guthrie and Alexander Thompson and Siobhan Dumbreck and Angela Flynn and Phil Alderson and Moray Nairn and Shaun Treweek and Katherine Payne",
note = "Funding: The National Institute for Health Research Health Services and Delivery Research programme.",
year = "2017",
month = "4",
doi = "10.3310/hsdr05160",
language = "English",
volume = "5",
series = "Health Services and Delivery Research",
publisher = "National Institute for Health Research",
number = "16",

}

TY - BOOK

T1 - Better guidelines for better care

T2 - accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling

AU - Guthrie, Bruce

AU - Thompson, Alexander

AU - Dumbreck, Siobhan

AU - Flynn, Angela

AU - Alderson, Phil

AU - Nairn, Moray

AU - Treweek, Shaun

AU - Payne, Katherine

N1 - Funding: The National Institute for Health Research Health Services and Delivery Research programme.

PY - 2017/4

Y1 - 2017/4

N2 - Background:Multimorbidity is common but most clinical guidelines focus on single diseases.Aim:To test the feasibility of new approaches to developing single-disease guidelines to better account for multimorbidity.Design:Literature-based and economic modelling project focused on areas where multimorbidity makes guideline application problematic.Methods:(1) Examination of accounting for multimorbidity in three exemplar National Institute for Health and Care Excellence guidelines (type 2 diabetes, depression, heart failure); (2) examination of the applicability of evidence in multimorbidity for the exemplar conditions; (3) exploration of methods for comparing absolute benefit of treatment; (4) incorporation of treatment pay-off time and competing risk of death in an exemplar economic model for long-term preventative treatments with slowly accruing benefit; and (5) development of a discrete event simulation model-based cost-effectiveness analysis for people with both depression and coronary heart disease.Results:(1) Comorbidity was rarely accounted for in the clinical research questions that framed the development of the exemplar guidelines, and was rarely accounted for in treatment recommendations. Drug–disease interactions were common only for comorbid chronic kidney disease, but potentially serious drug–drug interactions between recommended drugs were common and rarely accounted for in guidelines. (2) For all three conditions, the trials underpinning treatment recommendations largely excluded older, more comorbid and more coprescribed patients. The implications of low applicability varied by condition, with type 2 diabetes having large differences in comorbidity, whereas potentially serious drug–drug interactions were more important for depression. (3) Comparing absolute benefit of treatments for different conditions was shown to be technically feasible, but only if guideline developers are willing to make a number of significant assumptions. (4) The lifetime absolute benefit of statins for primary prevention is highly sensitive to the presence of both the direct treatment disutility of taking a daily tablet and competing risk of death. (5) It was feasible to use a discrete event simulation-based model to represent the relevant care pathways to estimate the relative cost-effectiveness of pharmacological treatments of major depressive disorder in primary care for patients who are also likely to go on and receive treatment for coronary heart disease but the analysis was reliant on eliciting some parameter values from experts, which increases the inherent uncertainty in the results. The key limitation was that real-life use in guideline development was not examined.Conclusions:Guideline developers could feasibly (1) use epidemiological data characterising the guideline population to inform consideration of applicability and interactions; (2) systematically compare the absolute benefit of long-term preventative treatments to inform decision-making in people with multimorbidity and high treatment burden; and (3) modify the output from economic models used in guideline development to examine time to benefit in terms of the pay-off time and varying competing risk of death from other conditions.Future work:Further research is needed to optimise presentation of comparative absolute benefit information to clinicians and patients, to evaluate the use of epidemiological and time-to-benefit data in guideline development, to better quantify direct treatment disutility and to better quantify benefit and harm in people with multimorbidity.

AB - Background:Multimorbidity is common but most clinical guidelines focus on single diseases.Aim:To test the feasibility of new approaches to developing single-disease guidelines to better account for multimorbidity.Design:Literature-based and economic modelling project focused on areas where multimorbidity makes guideline application problematic.Methods:(1) Examination of accounting for multimorbidity in three exemplar National Institute for Health and Care Excellence guidelines (type 2 diabetes, depression, heart failure); (2) examination of the applicability of evidence in multimorbidity for the exemplar conditions; (3) exploration of methods for comparing absolute benefit of treatment; (4) incorporation of treatment pay-off time and competing risk of death in an exemplar economic model for long-term preventative treatments with slowly accruing benefit; and (5) development of a discrete event simulation model-based cost-effectiveness analysis for people with both depression and coronary heart disease.Results:(1) Comorbidity was rarely accounted for in the clinical research questions that framed the development of the exemplar guidelines, and was rarely accounted for in treatment recommendations. Drug–disease interactions were common only for comorbid chronic kidney disease, but potentially serious drug–drug interactions between recommended drugs were common and rarely accounted for in guidelines. (2) For all three conditions, the trials underpinning treatment recommendations largely excluded older, more comorbid and more coprescribed patients. The implications of low applicability varied by condition, with type 2 diabetes having large differences in comorbidity, whereas potentially serious drug–drug interactions were more important for depression. (3) Comparing absolute benefit of treatments for different conditions was shown to be technically feasible, but only if guideline developers are willing to make a number of significant assumptions. (4) The lifetime absolute benefit of statins for primary prevention is highly sensitive to the presence of both the direct treatment disutility of taking a daily tablet and competing risk of death. (5) It was feasible to use a discrete event simulation-based model to represent the relevant care pathways to estimate the relative cost-effectiveness of pharmacological treatments of major depressive disorder in primary care for patients who are also likely to go on and receive treatment for coronary heart disease but the analysis was reliant on eliciting some parameter values from experts, which increases the inherent uncertainty in the results. The key limitation was that real-life use in guideline development was not examined.Conclusions:Guideline developers could feasibly (1) use epidemiological data characterising the guideline population to inform consideration of applicability and interactions; (2) systematically compare the absolute benefit of long-term preventative treatments to inform decision-making in people with multimorbidity and high treatment burden; and (3) modify the output from economic models used in guideline development to examine time to benefit in terms of the pay-off time and varying competing risk of death from other conditions.Future work:Further research is needed to optimise presentation of comparative absolute benefit information to clinicians and patients, to evaluate the use of epidemiological and time-to-benefit data in guideline development, to better quantify direct treatment disutility and to better quantify benefit and harm in people with multimorbidity.

U2 - 10.3310/hsdr05160

DO - 10.3310/hsdr05160

M3 - Other Report

VL - 5

T3 - Health Services and Delivery Research

BT - Better guidelines for better care

PB - National Institute for Health Research

ER -